Johnson & Johnson Vision’s TearScience, LipiScan® and LipiFlow® are now available to image meibomian glands and treat meimbomian gland dysfunction.
Meibomian gland dysfunction (MGD) is a primary cause of dry eye disease, which impacts more than 340 million people globally.
It is an incredible opportunity to help patients and achieve practice growth.
MGD is a leading cause of dry eye, found in an estimated 86% of dry eye patients. The LipiFlow® System is a best-in-class medical device treatment for MGD shown to improve mean gland function and dry eye symptoms. The efficacy of LipiFlow® is supported by 30 peer-reviewed reports. LipiScan® is the first and only dedicated rapid high definition gland imager.
